Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BAY 73-6691 is an inhibitor of brain penetrant PDE9A.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 819 | 5日内发货 | ||
25 mg | ¥ 5,910 | 6-8周 | ||
50 mg | ¥ 7,680 | 6-8周 | ||
100 mg | ¥ 12,600 | 6-8周 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,370 | 5日内发货 |
产品描述 | BAY 73-6691 is an inhibitor of brain penetrant PDE9A. |
体外活性 | BAY 73-6691 dose-dependently attenuates oxidative stress induced by Aβ25-35. The BAY 73-6691 dose-dependently alleviates cell viability loss due to Aβ25-35 treatment. The BAY 73-6691 attenuates Aβ25-35-induced increase of apoptosis cells[1]. It is found that when SH-SY5Y cells are cultured by Aβ25-35, a high degree of cell apoptosis is observed, while additional stimulation with BAY 73-6691 causes attenuation of cell apoptosis. BAY 73-6691 at 200 μg/mL almost neutralizes Aβ25-35-induced oxidative damage. |
体内活性 | BAY 73-6691 dose-dependently improves the acquisition performance in the Aβ25-35-injected mice on days 7 to 10 (day 7, F(5,54)=65.153; day 8, F(5,54)=62.340; day 9, F(5,54)=37.529; day 10, F(5,54)=38.624; P<0.001) and it also dose-dependently elevates the Aβ25-35-induced decrease of the dwell time on the 10th day post Aβ25-35 injection (day 10, F(5,54)=27.360, P<0.001). BAY 73-6691 at 3 mg/kg can almost completely abolish the prolongation of escape-latency on days 9 to 10. Results reveal that the Aβ25-35 injection. BAY 73-6691 alleviates Aβ25-35-induced abnormalities of the above indices. BAY 73-6691 treatment cause no influence on the swimming speed. Treatment with BAY 73-6691 does not cause detectable alteration of spatial memory in sham mice. The BAY 73-6691 causes no influence on the four indices mentioned above in sham mice and it has no significant effect on the apoptosis of hippocampal neurons in sham mice[1]. |
别名 | (R)-BAY 73-6691 |
分子量 | 356.73 |
分子式 | C15H12ClF3N4O |
CAS No. | 794568-92-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 160 mg/mL (448.52 mM), Sonication and heating are recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.8032 mL | 14.0162 mL | 28.0324 mL | 70.081 mL |
5 mM | 0.5606 mL | 2.8032 mL | 5.6065 mL | 14.0162 mL | |
10 mM | 0.2803 mL | 1.4016 mL | 2.8032 mL | 7.0081 mL | |
20 mM | 0.1402 mL | 0.7008 mL | 1.4016 mL | 3.5041 mL | |
50 mM | 0.0561 mL | 0.2803 mL | 0.5606 mL | 1.4016 mL | |
100 mM | 0.028 mL | 0.1402 mL | 0.2803 mL | 0.7008 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BAY 73-6691 794568-92-6 Metabolism PDE BAY 736691 (R)-BAY 73-6691 BAY 73 6691 Inhibitor inhibitor inhibit